In recent years, scientists have discovered a new class of molecules which are able to exert control over the degradation of proteins within cells and achieve unique pharmacological effects. This exciting field of drug discovery has rapidly matured and the first candidate molecules are now being tested in clinical trials.
For the third conference of this series, we will bring together an exciting line up of academics and industrial speakers. They will share their cutting-edge science in the field of protein degradation covering a range of topics from understanding the underlying biological processes involved to delivering degraders into the clinic.
The organising committee are seeking additional high-quality speakers from academia and industry. Potential contributors are invited to send an abstract of maximum one A4 page detailing the content of their proposed presentation with the subject line “Targeting protein degradation 3 – abstract submission” to email@example.com. The deadline for abstracts is Monday 31 January. An abstract template can be downloaded here.
This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly advancing field. It is targeted at academic and industrial scientists engaged in all aspects of research into protein degradation and those interested in broadening their knowledge in this field of drug discovery.
This event is being held back to back with "What's new in immunotherapies 2022".
Rational discovery and design of Targeted Protein Degraders
Dr Elisabetta Chiarparin. AstraZeneca
Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications
Dr Matt Weiss, Kymera Therapeutics
Pushing boundaries via academic-industry collaborations : From chemical probes to in vivo active degraders
Dr Will Farnaby, University of Dundee
Chemoproteomic approaches to interrogate the degradable kinome
Dr Fleur Fergusson, U.C. San Diego
Integration of high-throughput PROTAC synthesis and direct to biology assaying for rapidly evaluating targeted protein degradation
Dr Afjal Miah, GlaxoSmithKline
Dr Roy Pollock, C4
Speaker to be confirmed, Amphista Therapeutics
Speaker to be confirmed, Dunad Therapeutics
14/15 Belgrave Square
Tel: +44 (0)20 7598 1561
SCI Members attending this meeting are able to claim CPD points.
Nicola Chessum, SCI/Boehringer Ingelheim
Martin Lowe, SCI/ UCB
Jayshree Mistry, SCI
Jamie Scott, SCI/AstraZeneca
For further information and prices, please email firstname.lastname@example.org.